Post-trial access to treatment: How managed access programs could be a solution

How should access to antiretroviral treatment be measured?

How the WTO Could Be Improved

AbstractThis paper examines the impasse in the current Doha Development Round negotiations andasks how the rules of the WTO could be changed to facilitate multilateral negotiations andto increase the welfare of the Member countries. It considers possible changes to the methodof negotiation. As examples of rules which are outdated, it considers the rules relating toregional trade agreements and ...

Reasons Why Post-Trial Access to Trial Drugs Should, or Need not be Ensured to Research Participants: A Systematic Review

Background: researchers and sponsors increasingly confront the issue of whether participants in a clinical trial should have post-trial access (PTA) to the trial drug. Legislation and guidelines are inconsistent, ambiguous or silent about many aspects of PTA. Recent research highlights the potential importance of systematic reviews (SRs) of reason-based literatures in informing decision-making ...

The challenge of assuring continued post-trial access to beneficial treatment.

how the wto could be improved

abstractthis paper examines the impasse in the current doha development round negotiations andasks how the rules of the wto could be changed to facilitate multilateral negotiations andto increase the welfare of the member countries. it considers possible changes to the methodof negotiation. as examples of rules which are outdated, it considers the rules relating toregional trade agreements and ...